Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
CONCLUSIONS: We are highly confident that, compared to placebo, two-year treatment with natalizumab, cladribine, or alemtuzumab decreases relapses more than with other DMTs. We are moderately confident that a two-year treatment with natalizumab may slow disability progression. Compared to those on placebo, people with RRMS treated with most of the assessed DMTs showed a higher frequency of treatment discontinuation due to AEs: we are moderately confident that this could happen with fingolimod, teriflunomide, interferon beta-1a, laquinimod, natalizumab and daclizumab, while our certainty with other DMTs is lower. We are also moderately certain that treatment with alemtuzumab is associated with fewer discontinuations due to adverse events than placebo, and moderately certain that interferon beta-1b probably results in a slight reduction in people who experience serious adverse events, but our certainty with regard to other DMTs is lower. Insufficient evidence is available to evaluate the efficacy and safety of DMTs in a longer term than two years, and this is a relevant issue for a chronic condition like MS that develops over decades. More than half of the included studies were sponsored by pharmaceutical companies and this may have influenced their results. Further studies should focus on direct comparison between active agents, with follow-up of at least three years, and assess other patient-relevant outcomes, such as quality of life and cognitive status, with particular focu...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Marien Gonzalez-Lorenzo Ben Ridley Silvia Minozzi Cinzia Del Giovane Guy Peryer Thomas Piggott Matteo Foschi Graziella Filippini Irene Tramacere Elisa Baldin Francesco Nonino Source Type: research
More News: Avonex | Betaseron | Copaxone | Databases & Libraries | Disability | General Medicine | Gilenya | Methotrexate | Minocycline | Multiple Sclerosis | Rebif | Rituxan | Solodyn | Study | Tysabri